Edwards Lifesciences, Inc. EW presented results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards ...

Please provide your email address to receive an email when new articles are posted on . A new generation of a balloon-expandable transcatheter aortic valve replacement system reduced paravalvular leak ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...

LONDON--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR ...

SAN FRANCISCO, March 11 (Reuters) - Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three ...

Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Edwards Lifesciences shared its outlook for 2023 at its investor day, and considering our projections for the various product lines and earnings remain bounded by management’s estimates, we’re leaving ...